Publisher: Medscape


New Test Helps Catch Whooping Cough

In the Media Icon

A newly cleared point-of-care test will enable rapid identification of whooping cough, according to a press release from manufacturer Roche.


Trial: mRNA Flu Vaccines More Effective Than Quad

In the Media Icon

An mRNA influenza vaccine was approximately 35% more effective than an inactivated quadrivalent flu vaccine against two different strains, based on new data from a phase 3 randomized trial.


How Does EBV Cause Multiple Sclerosis — Hit and Run or Chronic Driver?

In the Media Icon

Andrew Wilner is an associate professor of neurology at the University of Tennessee Health Science Center, Memphis, and a seasoned neurologist and epilepsy expert who has mastered the less conventional locum career path.


Two or More Missed Milestones? Simple Rule Predicts Which Babies Will Catch Up and Which Won’t

In the Media Icon

Infants who demonstrate delays in multiple domains between 9 and 12 months are significantly more likely to still show persistent challenges at follow-up, according to findings from a large population-based study in Israel.


Second Dose Boosts Shingles Protection in Adults Aged 65 Years or Older

In the Media Icon

The recombinant herpes zoster vaccine is effective in older adults regardless of a patient’s immunocompromised status, based on data from more than 3 million adults aged 65 years or older.


Refractory, Intractable, Resistant: Consistent and Hopeful Headache Definitions Matter

In the Media Icon

Today, we are continuing our updates from the recent American Headache Society annual meeting.


The Glymphatic System: Not a Typo, the Brain’s Lymphatic System

In the Media Icon

Andrew Wilner is an associate professor of neurology at the University of Tennessee Health Science Center, Memphis, and a seasoned neurologist and epilepsy expert who has mastered the less conventional locum career path.


RSV Vaccine Effectiveness Wanes Early in Older Adults

In the Media Icon

For older adults, the vaccine against respiratory syncytial virus (RSV) appears to be most effective in the first year after administration, according to new research that shows the benefits of the immunization fall roughly 60% within about 1.5 years.